Evidence map›Paper›PMID 41234196›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Camelia Savulescu, Iris Ganser, Nathalie Nicolay, Adrien Lajot, Sandra Campos, Iván Martínez-Baz, Ana Paula Rodrigues, Mathil Vandromme, Marta Cara-Rodríguez, Aitziber Echeverría and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Camelia SavulescuEpidemiology department, Epiconcept, Paris, France.
Iris GanserEpidemiology department, Epiconcept, Paris, France.
Nathalie NicolayEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Adrien LajotEpidemiology of Infectious Diseases, Sciensano, Brussels, Belgium.
Sandra CamposNational School of Health - Institute of Health Carlos III, Madrid, Spain.
Iván Martínez-BazInstituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
Ana Paula RodriguesEpidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Mathil VandrommeEpidemiology of Infectious Diseases, Sciensano, Brussels, Belgium.
Marta Cara-RodríguezComplejo Hospitalario Universitario de Cáceres, Cáceres, Spain.
Aitziber EcheverríaInstituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
Vânia GaioEpidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Marie-Pierre ParsyCentre Hospitalier de Wallonie Picarde, Tournai, Belgium.
Ana Roldan GarridoServicio de Vigilancia y Salud Laboral, Dirección General de Salud Pública y Ordenación Farmacéutica, Consejería de Sanidad, Presidencia y Emergencias, Andalucía, Seville, Spain.
Jesús CastillaInstituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
Raquel GuiomarNational Reference Laboratory for Influenza and other Respiratory Virus, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Sabrina BacciEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Angela Mc RoseEpidemiology department, Epiconcept, Paris, France.
VEBIS hospital network RSV IE groupThe members of the VEBIS hospital network RSV IE group are listed under Collaborators.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We measured effectiveness of nirsevimab against laboratory-confirmed respiratory syncytial virus (RSV) infection in a test-negative case-control study among children aged < 24 months hospitalised for severe acute respiratory infection in three European countries. The overall effectiveness in the 2024/25 season among 2,201 children was 79% (95% CI: 58 to 89) and 85%, 78% and 69% at < 30, 30-89 and 90-215 days since immunisation. Immunisation was effective for preventing RSV-related hospitalisation in children, but effectiveness by time since immunisation needs monitoring in future seasons.

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsRespiratory Syncytial VirusesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsAcute DiseaseCase-Control StudiesChild, PreschoolEuropeFemaleHospitalizationHumansInfantMalePalivizumabAntibodies, Monoclonal, HumanizedAntiviral AgentsPalivizumabEuropemonoclonal antibodies, nirsevimab, effectivenessRSV

Identifiers

PMID41234196
PMCPMC12633706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.